BRIEF-Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score
Reuters
Mar 01
BRIEF-Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score
March 1 (Reuters) - Upstream Bio Inc UPB.O:
UPSTREAM BIO PRESENTS ADDITIONAL ANALYSES FROM THE PHASE 2 VIBRANT TRIAL OF VEREKITUG IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AT 2026 AAAAI ANNUAL MEETING
UPSTREAM BIO INC - PRIMARY ENDPOINT SHOWED REDUCTION OF -1.95 IN NASAL POLYP SCORE
UPSTREAM BIO INC - SECONDARY ENDPOINTS SHOWED REDUCTION IN NASAL CONGESTION SCORE BY -0.96
Source text: ID:nGNX42BmTQ
Further company coverage: UPB.O
((Reuters.Briefs@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.